The mass of regenerating tissues, such as bone, is critically dependent on the number of executive cells, which in turn is determined by the rate of replication of progenitors and the life-span of mature cells, reflecting the timing of death by apoptosis. Bone mass can be increased by intermittent parathyroid hormone (PTH) administration, but the mechanism of this phenomenon has remained unknown. We report that daily PTH injections in mice with either normal bone mass or osteopenia due to defective osteoblastogenesis increased bone formation without affecting the generation of new osteoblasts. Instead, PTH increased the life-span of mature osteoblasts by preventing their apoptosis — the fate of the majority of these cells under normal conditions. The antiapoptotic effect of PTH was sufficient to account for the increase in bone mass, and was confirmed in vitro using rodent and human osteoblasts and osteocytes. This evidence provides proof of the basic principle that the work performed by a cell population can be increased by suppression of apoptosis. Moreover, it suggests novel pharmacotherapeutic strategies for osteoporosis and, perhaps, other pathologic conditions in which tissue mass diminution has compromised functional integrity.
Robert L. Jilka, Robert S. Weinstein, Teresita Bellido, Paula Roberson, A. Michael Parfitt, Stavros C. Manolagas
Title and authors | Publication | Year |
---|---|---|
Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss
L Wang, S Liu, LD Quarles, RF Spurney |
American journal of physiology. Endocrinology and metabolism | 2004 |
Parathyroid Hormone Secretion and Action: Evidence for Discrete Receptors for the Carboxyl-Terminal Region and Related Biological Actions of Carboxyl-Terminal Ligands
TM Murray, LG Rao, P Divieti, FR Bringhurst |
Endocrine reviews | 2004 |
Allelic differences in a quantitative trait locus affecting insulin-like growth factor-I impact skeletal acquisition and body composition
CJ Rosen, C Ackert-Bicknell, WG Beamer, T Nelson, M Adamo, P Cohen, ML Bouxsein, MC Horowitz |
Pediatric Nephrology | 2004 |
Drugs Used to Treat Osteoporosis: The Critical Need for a Uniform Nomenclature Based on Their Action on Bone Remodeling
BL Riggs, AM Parfitt |
Journal of Bone and Mineral Research | 2004 |
Kinase-mediated transcription, activators of nongenotropic estrogen-like signaling (ANGELS), and osteoporosis: A different perspective on the HRT dilemma
SC Manolagas, S Kousteni, JR Chen, M Schuller, L Plotkin, T Bellido |
Kidney International | 2004 |
Parathyroid hormone: a double-edged sword for bone metabolism
L Qin, LJ Raggatt, NC Partridge |
Trends in Endocrinology & Metabolism | 2004 |
Teriparatide (Biosynthetic Human Parathyroid Hormone 1-34): A New Paradigm in the Treatment of Osteoporosis
KT Brixen, B Christensen, C Ejersted, BL Langdahl |
Pharmacology and Toxicology | 2004 |
Inhibition of growth and differentiation of osteoprogenitors in mouse bone marrow stromal cell cultures by increased donor age and glucocorticoid treatment
TL Chen |
Bone | 2004 |
Harnessing the parathyroids to create stronger bones
J Silver, D Bushinsky |
Current Opinion in Nephrology and Hypertension | 2004 |
Butyrate response factor 1 is regulated by parathyroid hormone and bone morphogenetic protein-2 in osteoblastic cells
S Reppe, OK Olstad, E Rian, VT Gautvik, KM Gautvik, R Jemtland |
Biochemical and Biophysical Research Communications | 2004 |
Osteoclastic cortical erosion as a determinant of subperiosteal osteoblastic bone formation in the femoral neck’s response to BMU imbalance. Effects of stance-related loading and hip fracture
J Power, N Loveridge, A Lyon, N Rushton, M Parker, J Reeve |
Osteoporosis International | 2004 |
Therapeutic potential of parathyroid hormone
F Cosman, R Lindsay |
Current Osteoporosis Reports | 2004 |
Matrix Metalloproteinases (MMPs) Safeguard Osteoblasts from Apoptosis during Transdifferentiation into Osteocytes: MT1-MMP Maintains Osteocyte Viability
MA Karsdal, TA Andersen, L Bonewald, C Christiansen |
DNA and Cell Biology | 2004 |
Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate
B Ettinger, SJ Martin, G Crans, I Pavo |
Journal of Bone and Mineral Research | 2004 |
Osteoarthritis and osteoporosis in postmenopausal women: clinical similarities and differences
D Avci, GA Bachmann |
Menopause | 2004 |
Effects of h-PTH on cancellous bone mass, connectivity, and bone strength in ovariectomized rats with and without sciatic-neurectomy
Y Kasukawa, N Miyakoshi, E Itoi, T Tsuchida, Y Tamura, T Kudo, K Suzuki, A Seki, K Sato |
Journal of Orthopaedic Research | 2004 |
Intermittent parathyroid hormone (1–34) enhances mechanical strength and density of new bone after distraction osteogenesis in rats
C Seebach, R Skripitz, TT Andreassen, P Aspenberg |
Journal of Orthopaedic Research | 2004 |
Maintenance of Increased Bone Mass After Recombinant Human Parathyroid Hormone (1-84) With Sequential Zoledronate Treatment in Ovariectomized Rats
Y Rhee, YY Won, MH Baek, SK Lim |
Journal of Bone and Mineral Research | 2004 |
Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation
MK Sutherland, JC Geoghegan, C Yu, E Turcott, JE Skonier, DG Winkler, JA Latham |
Bone | 2004 |
Does bone resorption inhibition affect the anabolic response to parathyroid hormone?
TJ Martin |
Trends in Endocrinology & Metabolism | 2004 |
Modeling the interactions between osteoblast and osteoclast activities in bone remodeling
V Lemaire, FL Tobin, LD Greller, CR Cho, LJ Suva |
Journal of Theoretical Biology | 2004 |
Parathyroid Hormone for the Treatment of Osteoporosis
M McClung |
Obstetrical & Gynecological Survey | 2004 |
Bone Cell Survival in Microgravity: Evidence that Modeled Microgravity Increases Osteoblast Sensitivity to Apoptogens
MA Bucaro, J Fertala, CS Adams, M Steinbeck, P Ayyaswamy, K Mukundakrishnan, IM Shapiro, MV Risbud |
Annals of the New York Academy of Sciences | 2004 |
Vitamin D inhibits Fas ligand-induced apoptosis in human osteoblasts by regulating components of both the mitochondrial and Fas-related pathways
G Duque, KE Abdaimi, JE Henderson, A Lomri, R Kremer |
Bone | 2004 |
CLINICAL USE OF TERIPARATIDE IN THE REAL WORLD: INITIAL INSIGHTS
PD Miller, JP Bilezikian, C Deal, ST Harris, RP ci |
Endocrine Practice | 2004 |
Principles of Gender-Specific Medicine
G Supinski, LA Callahan |
Principles of Gender-Specific Medicine | 2004 |
Agentes anabólicos óseos para el tratamiento de osteoporosis
JM Quesada |
Endocrinología y Nutrición | 2004 |
Glucocorticoïdes et os
P Orcel |
Annales d'Endocrinologie | 2004 |
PerspectiveParathyroid hormone—a drug for orthopedic surgery?
R Skripitz, P Aspenberg |
Acta Orthopaedica Scandinavica | 2004 |
Teriparatide for Severe Osteoporosis
KA Cappuzzo, JC Delafuente |
The Annals of pharmacotherapy | 2004 |
Transient Versus Sustained Phosphorylation and Nuclear Accumulation of ERKs Underlie Anti- Versus Pro-apoptotic Effects of Estrogens
JR Chen, LI Plotkin, JI Aguirre, L Han, RL Jilka, S Kousteni, T Bellido, SC Manolagas |
The Journal of biological chemistry | 2004 |
Telomerized presenescent osteoblasts prevent bone mass loss in vivo
K Yudoh, K Nishioka |
Gene Therapy | 2004 |
Effects of Tunicamycin, Mannosamine, and Other Inhibitors of Glycoprotein Processing on Skeletal Alkaline Phosphatase in Human Osteoblast-Like Cells
JR Farley, P Magnusson |
Calcified Tissue International | 2004 |
Osteoporosis: A Review
JT Lin, JM Lane |
Clinical Orthopaedics and Related Research® | 2004 |
The Skeleton
EJ Massaro, JM Rogers |
2004 | |
Molekularmedizinische Grundlagen von altersspezifischen Erkrankungen
D Ganten, K Ruckpaul, A Ruiz-Torres |
2004 | |
Effects of 1α,25-Dihydroxyvitamin D3 and Growth Hormone on Apoptosis and Proliferation in UMR 106 Osteoblast-Like Cells
O Morales, MK Samuelsson, U Lindgren, LA Haldosén |
Endocrinology | 2004 |
Bone Formation
F Bronner, MC Farach-Carson |
2004 | |
The Biology of Skeletal Metastases
ET Keller, LW Chung |
2004 |